Integrated Neurohormonal Approach to the Treatment of Obesity: The Amylin Agonist Pramlintide and Its Interactions with Leptin and PYY Signaling Pathways

[1]  J. Halford,et al.  Pharmacology of appetite suppression. , 2000, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[2]  J. Ohannesian,et al.  Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. , 1996, The Journal of clinical investigation.

[3]  T. Rink,et al.  Diabetogenic effects of salmon calcitonin are attributable to amylin-like activity. , 1995, Metabolism: clinical and experimental.

[4]  A. Young,et al.  Synergy between amylin and cholecystokinin for inhibition of food intake in mice , 1998, Physiology & Behavior.

[5]  A. Kelley,et al.  Corticostriatal-hypothalamic circuitry and food motivation: Integration of energy, action and reward , 2005, Physiology & Behavior.

[6]  D. Cummings,et al.  Gastrointestinal regulation of food intake. , 2007, The Journal of clinical investigation.

[7]  J M Polak,et al.  Human distribution and release of a putative new gut hormone, peptide YY. , 1985, Gastroenterology.

[8]  S. Adams,et al.  PYY[3-36] administration decreases the respiratory quotient and reduces adiposity in diet-induced obese mice. , 2006, The Journal of nutrition.

[9]  K. Docherty,et al.  Processing of pro‐islet amyloid polypeptide (proIAPP) by the prohormone convertase PC2 , 1996, FEBS letters.

[10]  Clifford B. Saper,et al.  Unraveling the central nervous system pathways underlying responses to leptin , 1998, Nature Neuroscience.

[11]  S. Woods,et al.  Insulin and leptin as adiposity signals. , 2004, Recent progress in hormone research.

[12]  S. Doran,et al.  Low‐dose Pramlintide Reduced Food Intake and Meal Duration in Healthy, Normal‐Weight Subjects , 2007, Obesity.

[13]  Zhuowei Wang,et al.  Modulation of Circulating Leptin Levels by Its Soluble Receptor* , 2001, The Journal of Biological Chemistry.

[14]  E. C. Stein,et al.  Long‐term weight control study III (weeks 104 to 156) , 1992 .

[15]  Henry C. Lin,et al.  Cholecystokinin and peptide YY are released by fat in either proximal or distal small intestine in dogs , 2003, Regulatory Peptides.

[16]  R. Unger,et al.  Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment. , 1990, The Journal of clinical investigation.

[17]  J. Flier,et al.  Identification of SOCS-3 as a potential mediator of central leptin resistance. , 1998, Molecular cell.

[18]  C. Beglinger,et al.  Two molecular forms of Peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1–36 and PYY 3–36 , 1994, Regulatory Peptides.

[19]  A. Bado,et al.  The stomach is a source of leptin , 1998, Nature.

[20]  R. Krauss,et al.  Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Mars,et al.  Fasting leptin and appetite responses induced by a 4-day 65%-energy-restricted diet , 2006, International Journal of Obesity.

[22]  P. Gorden,et al.  Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. , 2005, Diabetes.

[23]  T. Moran,et al.  Leptin enhances feeding suppression and neural activation produced by systemically administered bombesin. , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.

[24]  T. Lutz.  Pancreatic amylin as a centrally acting satiating hormone. , 2005, Current drug targets.

[25]  B. Smith,et al.  Rapid inhibition of neural excitability in the nucleus tractus solitarii by leptin: implications for ingestive behaviour , 2006, The Journal of physiology.

[26]  C. Mantzoros,et al.  Human leptin levels are pulsatile and inversely related to pituitary–ardenal function , 1997, Nature Medicine.

[27]  Andrew A. Young,et al.  Preclinical pharmacology of pramlintide in the rat: Comparisons with human and rat amylin , 1996 .

[28]  L. J. Duncan,et al.  A comparative trial of different regimens of fenfluramine and phentermine in obesity. , 1973, The Practitioner.

[29]  F. Lönnqvist,et al.  Leptin secretion from adipose tissue in women. Relationship to plasma levels and gene expression. , 1997, The Journal of clinical investigation.

[30]  W. Edwards,et al.  Valvular heart disease associated with fenfluramine-phentermine. , 1997, The New England journal of medicine.

[31]  K. Toshinai,et al.  The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. , 2005, Endocrinology.

[32]  J. Livesey,et al.  The isolation of human pituitary hormones from frozen glands. , 1981, The Journal of clinical endocrinology and metabolism.

[33]  A. Prentice,et al.  Effects of recombinant leptin therapy in a child with congenital leptin deficiency. , 1999, The New England journal of medicine.